In post #63941 I mentioned that I was using Yahoo
Post# of 72440
An updated comparison of the example I used shows:
BNTX - SP $45.4 dollars/ OS 227M/ MC 10.3B
IPIX – SP 10.7 cents/ OS 267M/ MC 28.6M
As I stated these 2 companies are apples and oranges having completely different drugs and approaches. Brilacidin has completed 3 separate phase 2 studies so IPIX is actually further along in the science. BNTX has much stronger financials as they have partnership deals in place which is exactly the point of post #63941. Once IPIX gets a cash infusion from a BP partnership or Government agency IMO we will be a multiple dollar company.